Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Qlife is positioned at the forefront of the fast-growing at-home diagnostics market, offering lab-grade biomarker testing with global potential. In light of recent additions to the Board of Directors, a successful capital raise, and regulatory clearance from UK authorities to begin clinical trials, the company is now announcing its upcoming roadmap. This roadmap outlines key growth areas with a strong focus on commercialization, regulatory milestones, and strategic partnerships. From expanding its presence in the Chinese Hospital-at-Home segment to pioneering immunodiagnostic testing for chronic care, Qlife is laying the foundation for significant revenue generation and global leadership in decentralized healthcare.
Qlife is a first mover in the growing market for at-home, lab-grade biomarker testing. The company's strategic roadmap focuses on the following areas:
- Hospital-at-Home - China market
- Egoo Phe Test - first ever self-test immuno-Dx for chronic condition management
- Partnerships - enabling global distribution
- Partner technology collaboration - support of global market entries
Hospital-at-Home China market
The Chinese market for decentralized testing exceeded EUR 2 billion in 2023, driven by an aging population. The roadmap focuses on executing key steps to introduce the Egoo Health platform to the Chinese Hospital-at-Home and pharmacy markets as soon as possible. The company will receive royalties on net sales from its partner, Hipro Biotechnology, with a target volume of 10 million tests over the first five years.
First ever immuno-Dx test for chronic management
The Egoo Phe test, currently launched as a research-use-only product, continues to grow in both revenue and geographic reach. The test has been cleared in the UK to begin clinical trials, and the company expects to receive regulatory approval in early Q4 this year for the UK market, followed shortly by the EU. The total addressable market in the UK, EU, and Middle East exceeds SEK 1 billion, with additional potential in the U.S. and China.
Partnerships for global distribution
Qlife is in discussions with global IVD, pharma, and consumer health companies that have expressed interest in the company's platform for general health, with an early focus on women's health. Qlife's platform is considered highly innovative, addressing an unmet need for decentralized access to lab-grade data that supports the management of chronic diseases outside traditional healthcare institutions.
Hipro and Qlife technology collaborations
The two companies are collaborating with a strong focus on product solutions that will reinforce their first-mover position in the global self-testing and Hospital-at-Home markets. They are planning further integration and expect to continue introducing new technologies and solutions, emphasizing their joint commitment to becoming a leading force in the Hospital-at-Home space.